preclinical studies

Allterum Therapeutics is an early-stage biotechnology company developing precision oncology and inflammation therapeutics. Its lead program, 4A10, is an anti-CD127 monoclonal antibody targeting the CD127 pathway (IL-7 receptor complex) for relapsed leukemia, acute lymphoblastic leukemia, B-cell malignancies, lymphomas, and CD127-expressing solid tumors. The 4A10 antibody was developed at the National Cancer Institute and licensed exclusively to Fannin; Allterum is a Fannin portfolio company.

clinical developmentdrug developmentmonoclonal antibody developmenttranslational science

Arterez, Inc. is a Michigan biosciences group focused on the discovery and development of therapeutics and diagnostics against chronic vascular diseases, beginning with cardiovascular disease (CVD), by targeting upstream multifactorial root causes. Its platform involves proprietary combo therapies and multi-marker diagnostics addressing disruption of the endothelial glycocalyx.

biomarker panel developmentdiagnostics developmenttherapeutics discovery and development

Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure. It develops regenerative peptide drugs, led by TP508 (Rusalatide acetate, Chrysalin), to restore vascular function and activate stem cells. Incorporated in Delaware in 2012, it is based in Galveston, Texas.

clinical trialsdrug formulation/CMC developmentpeptide drug development

Clear Scientific is a biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body. Its lead candidate CS-1103 is a small-molecule sequestrant that binds and inactivates fentanyl, accelerating its removal from the body, and has shown positive Phase 2 results. Preclinical research also explores CS-1103 for methamphetamine overdose.

biopharmaceutical researchclinical trials

Curlim is a biotech company founded in 2024 as a spin-off from the University of Limoges, bringing together three PhD scientists and a C-level business person to address unmet needs in neurology, specifically hereditary peripheral neuropathies. Its first mission is developing CLM001, a nanomedicine for Charcot-Marie-Tooth disease type 1A (CMT1A), the most common inherited peripheral neuropathy.

drug developmentnanotechnology

Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class liver- and kidney-specific acetyl-CoA metabolic enzyme inhibitors. Its lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden. The company is led by a team with deep exper

drug developmentdrug discoveryin vivo and translational studies